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In Brief
 
Angiostatin Antagonizes 
Angiomotin
 
Work on angiogenesis inhibitors such
as angiostatin has generated a lot of
newspaper print, but rather less un-
derstanding about just how these mol-
ecules work. Now, Troyanovsky et al.
report on their discovery of angiomo-
tin, an angiostatin-binding protein
that appears to be a target for an-
giostatin action (page 1247). Angio-
motin is not a transmembrane pro-
tein, however, and does not appear to
act as a traditional signal-transducing
receptor for angiostatin.
Only cells that contain, or are trans-
fected with, angiomotin show the fol-
lowing responses to angiostatin: the
internalization of angiostatin, an in-
crease in FAK kinase activity, a re-
duction of both background and
growth-factor induced migration
rates, and an inhibition of tubulogen-
esis. As discussed in a comment by
Zetter (page F35), angiomotin’s local-
ization at the leading edge of migrat-
ing cells suggests that it is normally in-
volved in migration, and that the
binding of angiostatin to angiomotin
may disrupt this function. This would
interfere with the migrations of en-
dothelial cells involved in the initial
clustering step of angiogenesis.
 
Endostatin Antagonizes 
Itself, Trimerized
 
Endostatin, another angiogenesis in-
hibitor, is cleaved from the COOH
terminus of collagen XVIII (c18). The
longer of these cleavage products in-
cludes a trimerization motif, and in
 
this issue, Kuo et al. report that
 
this  trimerized form of endostatin
(termed the noncollagenous domain
1, or NC1) has promigratory activity
that is antagonized by monomeric en-
dostatin (page 1233). Ackley et al.
find support for a similar phenome-
non in the nervous system of 
 
Cae-
norhabditis elegans
 
 (page 1219).
Kuo et al. report that addition of
c18 NC1 prevents endothelial cells
from aggregating into tubules in
matrigel, and stimulates migration of
cells away from preformed tubules.
Similar migration and dissolution
events may be necessary to initiate
new tubule formation during angio-
genesis. Dimerized endostatin do-
mains have the same effects on motil-
ity, but endostatin monomers are
inactive and can actually inhibit mo-
tility induced by c18 NC1.
 
Ackley et al. perform a similar
 
experiment in worms mutant for
CLE-1, the worm homologue of c18.
 
These worms, which lack only the NC1
domain of CLE-1, show defects in cell
migration and axon guidance. Although
expression of CLE-1 NC1 in the mutant
worms rescues these defects, expression
of monomeric endostatin does not re-
sult in rescue. Instead, it prevents res-
cue by coexpressed CLE-1 NC1 and
causes dominant migration defects in a
wild-type background. The presence of
c18 in nematodes, which are avascular
and have no endothelial cells, indicates
that c18 and endostatin are clearly im-
portant for functions other than those
associated with endothelial cell and an-
giogenic functions.
Unlike other scatter factors, NC1
requires the presence of extracellular
matrix (ECM) for its in vitro activity.
There are two possible explanations
for this. NC1 may act by oligomeriz-
ing a cell surface receptor, which then
 
signals to interfere with an adhesive
signal from the ECM. Alternatively,
NC1 may associate with or oligomer-
ize an ECM component, thus modu-
lating the ECM’s ability to stimulate
migration via cell surface receptors.
An analysis of NC1-binding proteins
should allow differentiation between
these two models.
 
Integrins to the Rescue
 
Correcting myopathies by gene ther-
apy is a formidable task, given the ex-
tent of muscle as a target tissue. Re-
sults reported by Burkin et al. (page
1207) suggest an alternative strategy:
by increasing the production from an
endogenous gene unrelated to the
mutated gene, a genetic defect may be
at least partially corrected.
 
Burkin et al. start with mice that
lack both dystrophin and utrophin.
Humans with Duchenne muscular
dystrophy (DMD) have mutations
only in dystrophin, but the doubly
mutant mice are the best mimic of this
situation, as utrophin tends to substi-
tute for dystrophin function in singly
mutant mice. When Burkin et al. use
 
transgenesis to overproduce the 
 
a
 
7 in-
tegrin in the muscles of the doubly
mutant mice, they find that lifespan
increases threefold and there is im-
provement in other phenotypes asso- 
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ciated with muscle degeneration. This
is consistent with overlapping roles of
dystrophin and integrins in connecting
extracellular matrix to cytoskeleton.
The activity of integrin 
 
a
 
7 at the neu-
romuscular junction and in calcium
homeostasis may also be important.
Based on these results, gene therapy
with the smaller, more manageable in-
tegrin gene could be considered for
treating DMD. However, if a method
could be found to increase production
from endogenous integrin genes, gene
therapy might be avoided altogether.
 
HMG1 and Atherosclerosis
 
HMG1 is a small protein that binds to
and bends DNA. But HMG1 is also
known as an extracellular mediator of
endotoxin lethality and an inducer of
neurite outgrowth. Degryse et al. add
to this list on page 1197 with their re-
port on HMG1’s ability to induce
chemotaxis of rat smooth muscle cells
(SMCs) via binding to the receptor
for advanced glycation endproducts
(RAGE), suggesting a possible con-
nection to atherosclerosis.
SMCs contain little or no HMG1,
but they respond to exogenous
HMG1 with membrane ruffling, a re-
duction in the number of stress fibers,
 
cell polarization, and directed cell mi-
gration. Detergent-permeabilized and
necrotic cells release sufficient HMG1
to induce these effects. During athero-
sclerosis, HMG1 may be released
from the early macrophage infiltrate
and from the damaged and necrotic
endothelial cells that flank the SMCs
and are rich in HMG1.
Previously, RAGE had been im-
plicated in certain forms of athero-
sclerosis associated with diabetes.
The work of Degryse et al. suggests
that HMG1 may be an even more
important ligand for this receptor
than the advanced glycation end-
products that are produced during
hyperglycemia.
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